The Advantages of the MabPair™ Platform
Single-Drug Entity with the Power of Two Antibodies
- Bring the synergy of simultaneously targeting two pathways
- Allows different IgG isotypes and stoichiometry between the two antibodies, unlike bispecific antibodies
- Reduced cost compared to combination of two separate antibodies
Can Be Applied to Different Therapeutic Areas
- Oncology
- Immuno-Oncology
- Inflammation
- Infectious diseases
- Metabolic diseases